Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious ...

Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale ...

A recent study reveals thrombocytopenia as a significant prognostic factor in low-risk MDS, impacting survival and treatment ...

The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may ...

Key Takeaways An experimental drug can help many with a rare autoimmune bleeding conditionMore than half of people with immune thrombocytopenia wound up with healthy platelet levels after treatment ...

A late-breaking presentation at the American Society of Hematology (ASH) 2025 meeting revealed promising phase 3 findings for ...

Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly ...

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

"Patients with cancer-associated thrombosis are both at risk of recurrent venous thromboembolism and bleeding during extended ...

Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia (ITP) by 45%, according to data ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...